Literature DB >> 20732398

Chitosan as a carrier for targeted delivery of small interfering RNA.

Walter E Rudzinski1, Tejraj M Aminabhavi.   

Abstract

The recent discovery of RNA interference (RNAi) technology for gene therapy has triggered extensive research efforts for developing small interfering RNA (siRNA) loaded nanocomplexes of chitosan and its derivatives for silencing genes. Due to its large molecular weight (∼13 kDa) and polyanionic nature (∼40 negative phosphate groups), naked siRNA does not freely cross the cell membrane. Therefore, its efficient intracellular delivery requires suitable carriers to overcome the intrinsic, poor intracellular uptake and limited blood stability. Among viral and non-viral delivery vectors, the use of non-viral vectors such as chitosan or its derivatives is attractive, since these polymers are biodegradable, biocompatible, with low toxicity and high cationic potential. Even though much of the technology-base has been well established for targeted delivery of plasmid DNA using chitosan and its derivatives, only recently, has the technology been applied to the targeted delivery of siRNA. This review will explore the factors that are most important in enhancing transfection efficiency and cell specificity in vitro and in vivo including degree of deacetylation, molecular weight and chemical modification of chitosan, pH, and the charge ratio of chitosan to siRNA.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732398     DOI: 10.1016/j.ijpharm.2010.08.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  39 in total

1.  Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Authors:  Angela J Ziebarth; Somaira Nowsheen; Adam D Steg; Monjri M Shah; Ashwini A Katre; Zachary C Dobbin; Hee-Dong Han; Gabriel Lopez-Berestein; Anil K Sood; Michael Conner; Eddy S Yang; Charles N Landen
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

Review 2.  Current status of non-viral gene therapy for CNS disorders.

Authors:  Rahul Dev Jayant; Daniela Sosa; Ajeet Kaushik; Venkata Atluri; Arti Vashist; Asahi Tomitaka; Madhavan Nair
Journal:  Expert Opin Drug Deliv       Date:  2016-06-01       Impact factor: 6.648

3.  Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier.

Authors:  Christelle Zandanel; Magali Noiray; Christine Vauthier
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

4.  Biocompatible nanopolymers: the next generation of breast cancer treatment?

Authors:  Julia Y Ljubimova; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2012-10       Impact factor: 5.307

5.  Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung.

Authors:  Daisuke Ihara; Noboru Hattori; Yasushi Horimasu; Takeshi Masuda; Taku Nakashima; Tadashi Senoo; Hiroshi Iwamoto; Kazunori Fujitaka; Hirokazu Okamoto; Nobuoki Kohno
Journal:  Pharm Res       Date:  2015-07-03       Impact factor: 4.200

6.  Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.

Authors:  Ana Vanessa Nascimento; Amit Singh; Hassan Bousbaa; Domingos Ferreira; Bruno Sarmento; Mansoor M Amiji
Journal:  Acta Biomater       Date:  2016-09-30       Impact factor: 8.947

Review 7.  Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.

Authors:  Hui Yi Xue; Shimeng Liu; Ho Lun Wong
Journal:  Nanomedicine (Lond)       Date:  2014-02       Impact factor: 5.307

8.  Dendronized gold nanoparticles for siRNA delivery.

Authors:  Sung Tae Kim; Apiwat Chompoosor; Yi-Cheun Yeh; Sarit S Agasti; David J Solfiell; Vincent M Rotello
Journal:  Small       Date:  2012-08-08       Impact factor: 13.281

9.  Serratiopeptidase loaded chitosan nanoparticles by polyelectrolyte complexation: in vitro and in vivo evaluation.

Authors:  Nitin Mali; Preeti Wavikar; Pradeep Vavia
Journal:  AAPS PharmSciTech       Date:  2014-08-30       Impact factor: 3.246

10.  Ternary polymeric nanoparticles for oral siRNA delivery.

Authors:  Jing Zhang; Chunbai He; Cui Tang; Chunhua Yin
Journal:  Pharm Res       Date:  2013-01-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.